We are advancing a diversified pipeline of targeted oncology programs being evaluated as standalone and combination therapies.
Progressing two late-stage, potentially registrational clinical trials for patients with rare and debilitating tumors: desmoid tumors and neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Advancing our gamma secretase inhibitor as a potential cornerstone of anti-B-cell maturation antigen (BCMA) combination therapy in collaboration with industry leaders.
Metastatic Solid Tumors
Developing targeted therapies for the treatment of highly prevalent, genetically defined cancers, including those with RAS and RAF mutations.
We partner with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the potential of science and bring new therapies to underserved patients.